Apriori Bio

About:

Apriori Bio offers a platform for creating variant-resilient vaccines and provides real-time insights to prepare for future outbreaks.

Website: https://aprioribio.com

Twitter/X: AprioriBio

Top Investors: Flagship Pioneering, Coalition for Epidemic Preparedness Innovations

Description:

Apriori Bio is a health security company, aimed at protecting humanity against viral threats. The company uses a unique technology platform that enables the creation of variant-resilient vaccines and provides real-time insights to prepare for future outbreaks. Apriori Bio focuses on designing new vaccines and antibody drugs to combat existing and potential viral variants. With its innovative approach, the company aims to ensure durable protection against rapidly evolving viruses

Total Funding Amount:

$51.1M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2020-01-01

Contact Email:

info(AT)aprioribio.com

Founders:

Alex Goldsmith, Daniel Acker, Lovisa Afzelius, Noubar Afeyan

Number of Employees:

11-50

Last Funding Date:

2024-07-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai